Association of IL-6 -597 G/A Polymorphism with Cancer Risk: Evidence from a Meta-Analysis.
Although it has been suggested that the interleukin-6(IL-6) gene -597G/A polymorphism may be a risk factor for cancer, the conclusions from previous studies are inconsistent. To clarify the precise interrelation, we performed a comprehensive meta-analysis of 6 case-control studies involving 1,605 subjects (706 cases and 899 controls). The overall results showed no significant association between the IL6 -597G/A polymorphism and cancer risk in the overall population (CC vs GG: OR = 2.38, 95% CI = 0.62-9.14; CG vs GG: OR = 1.23, 95% CI = 0.66-2.27; dominant model: OR = 1.32, 95% CI = 0.63-2.79; recessive model: OR = 1.93, 95% CI = 0.72-v5.17). Subgroup analysis by ethnicity and cancer type yielded the same result. Therefore, the current evidence from this meta-analysis did not support the hypothesis of IL-6 -597G/A polymorphism as a risk factor of cancer. Conclusive evidence on the effects of this variant in cancer should be addressed in future studies.